The News

DBV Technologies stengthens board of Directors and Scientific Advisory Board

13/11/2007

Paris, France – 13 November 2007 – DBV Technologies (DBV), announced today that it has made several significant appointments to its Board of Directors (BOD) and Scientific Advisory Board (SAB).
DBV Technologies is developing its proprietary, patented VIASKIN® epicutaneous delivery technology primarily for the diagnosis and treatment of allergies and mass vaccination. Stéphane Thiroloix is appointed to the Board of Directors, while Richard Guy and Paul-Henri Lambert join the Scientific Advisory Board.
Newly appointed Board member Stéphane Thiroloix brings extensive strategic and operational experience in the pharmaceutical industry. He is presently Executive VP Corporate Development at Ipsen, heading preclinical, clinical and pharmaceutical development as well as business development, regulatory and legal affairs. Prior to his role at Ipsen, Mr. Thiroloix also fulfilled roles at Bristol Myers Squibb France and GlaxoSmithKline Europe.
Mr. Thiroloix joins another notable board member Torbjorn Bjerke, who provides further insight and expertise into the field of allergy treatment from his extensive allergy experience as CEO at the Swedish inflammatory diseases focused Biolipox, Executive Vice President of R&D at ALK-Abello and as a Director of Research at AstraZeneca.
As a new SAB appointment, Prof. Richard Guy increases DBV Technologies’ expertise in percutaneous administration, having contributed to breakthroughs in understanding of the skin and the in vivo evaluation of topical bioavailability. Prof. Guy is currently Head of Pharmacy and Pharmacology at the University of Bath, United Kingdom.
Finally Prof. Paul Henri Lambert, a specialist in vaccination and immunology, has also joined the SAB. He was previously Director of vaccine and vaccination research at the World Health Organisation (WHO). Between 2000 and 2004, Prof. Lambert was Coordinator of the European Commission’s European project on the Improvement of Neonatal Vaccination and has chaired the Steering Committee of the European Consortium for (TB) Vaccines (TBVAC) since 2004. He is Director of the annual global Advanced Course of Vaccinology co-sponsored by the B&M Gates Foundation and the European Commission.
The SAB, chaired by world-renowned expert in allergy diagnosis and neonatal care Prof. Christophe Dupont, now includes a full complement of six leading experts appointed to support DBV’s present and future objectives to become a leader in epicutaneous delivery and its applications in allergy diagnosis, allergy treatment and mass vaccination.
Commenting on the appointments to the board and scientific board, Jean François Biry, Chairman and CEO of DBV, said, “We are delighted that we have been able to attract such talented and renowned individuals. Our new BOD appointment significantly adds to DBV’s experience in clinical development while the combined SAB will provide DBV with extensive expertise in the areas of allergy diagnosis, vaccination, and dermatology. This knowledge and experience will be integral to the future of DBV Technologies, as we expand and mature our pipeline in the areas of allergy diagnosis, allergy desensitisation, vaccine delivery and cosmaceutical applications of our VIASKIN technology.”

For more information contact:
 
Northbank Communications:
 
Katja Stout/ Justine Lamond/ Holly Griffiths
 Tel: +44 (0)20 7268 3241
dbv@northbankcommunications.com

 
DBV Technologies:
 http://www.dbv-technologies.com/

Jean-François Biry, Chairman and CEO
 Tel: +33 (0)1 55 427878
jfbiry@dbv-technologies.com
 

About DBV Technologies
DBV Technologies, headquartered in Boulogne-Billancourt, near Paris, is a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is headed by Jean-François Biry, Chairman & CEO and was born out of the experience of Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV’s lead product, Diallertest® Milk, is on sale in France and several other countries for the diagnosis of cow’s milk protein allergy. The product represents a revolution in paediatrics and was awarded an International prize for Technological Innovation by the Altran foundation.

Founded in 2002, DBV Technologies has ca.30 employees and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement. For more information on cow’s milk protein allergy, visit http://allergieaulaitdevache.com/ and http://www.aplv-leblog.com/.

About VIASKIN®
The company has perfected and patented worldwide its VIASKIN® technology, a unique delivery system that retains the active compound on the carrier using electrostatic forces only. This allows active compounds to be delivered to the epidermis of the skin without breaking the blood-skin barrier. The Company has a pipeline of Diallertest® products geared for the diagnosis of other allergies including wheat, soya bean and dust mites. The VIASKIN® technology is in development for use in treating allergies through desensitisation and for the administration of vaccines. The company is currently seeking partnerships in these areas. The technology was awarded the Siemen’s prize for Innovation 2006.